Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platform with Zephyr’s analytics to accelerate biomarker discovery for oncology drug development and patient selection. The collaboration will integrate into Guardant’s Infinity AI capabilities and is positioned to improve predictions of therapy response and trial matching. The deal signals continued consolidation of molecular data and advanced analytics as key enablers for precision oncology R&D and for biopharma partners seeking faster, better informed trial design and biomarker strategies.